Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

RORγt is the key transcription factor controlling the development and function of CD4(+) Th17 and CD8(+) Tc17 cells. Across a range of human tumors, about 15% of the CD4(+) T cell fraction in tumor-infiltrating lymphocytes are RORγ+ cells. To evaluate the role of RORγ in antitumor immunity, we have...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Principais autores: Hu, Xiao, Liu, Xikui, Moisan, Jacques, Wang, Yahong, Lesch, Charles A., Spooner, Chauncey, Morgan, Rodney W., Zawidzka, Elizabeth M., Mertz, David, Bousley, Dick, Majchrzak, Kinga, Kryczek, Ilona, Taylor, Clarke, Van Huis, Chad, Skalitzky, Don, Hurd, Alexander, Aicher, Thomas D., Toogood, Peter L., Glick, Gary D., Paulos, Chrystal M., Zou, Weiping, Carter, Laura L.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215247/
https://ncbi.nlm.nih.gov/pubmed/28123897
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1254854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados